Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Juan‐Ramón Larrubia"'
Autor:
Julia Peña-Asensio, Henar Calvo-Sánchez, Joaquín Miquel-Plaza, Eduardo Sanz-de-Villalobos, Alejandro González-Praetorius, Alberto Delgado-Fernandez, Miguel Torralba, Juan-Ramón Larrubia
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundHBe-antigen(Ag)-negative chronic hepatitis B virus (HBV) infection is characterized by little liver fibrosis progression and vigorous HBV-multispecific CD8+ T-cell response.AimsTo assess whether HBsAg level could discriminate different HBeA
Externí odkaz:
https://doaj.org/article/15262ea5052547689d84e817db95f44b
Autor:
Julia Peña-Asensio, Henar Calvo-Sánchez, Joaquín Miquel, Eduardo Sanz-de-Villalobos, Alejandro González-Praetorius, Miguel Torralba, Juan-Ramón Larrubia
Publikováno v:
iScience, Vol 27, Iss 1, Pp 108666- (2024)
Summary: A rebalance between energy supply and demand in HBV-specific-CD8+ activated progenitor (AP) cells could restore the functionality of proliferative progeny (PP) in e-antigen(Ag)-negative chronic hepatitis B (CHBe(−)). We observed that quies
Externí odkaz:
https://doaj.org/article/23139e1d19c64b478d331bed8a645c18
Autor:
Julia Peña-Asensio, Henar Calvo, Miguel Torralba, Joaquín Miquel, Eduardo Sanz-de-Villalobos, Juan-Ramón Larrubia
Publikováno v:
Cells, Vol 10, Iss 3, p 538 (2021)
Hepatitis C virus (HCV)-specific CD8+ T cell response is essential in natural HCV infection control, but it becomes exhausted during persistent infection. Nowadays, chronic HCV infection can be resolved by direct acting anti-viral treatment, but ther
Externí odkaz:
https://doaj.org/article/ce21d3909f8d4757a80dc3f6d9d0c2b3
Autor:
Julia Peña‐Asensio, Henar Calvo, Joaquín Miquel, Eduardo Sanz‐de‐Villalobos, Alejandro González‐Praetorius, Miguel Torralba, Juan‐Ramón Larrubia
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:1545-1559
Publikováno v:
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
Sixteen months have passed since I had the honor of being appointed editor-in-chief of Revista Española de Enfermedades Digestivas (Spanish Journal of Gastroenterology) and thank the Spanish Society of Digestive Diseases (SEPD) for trusting me in th
Autor:
Julia, Peña-Asensio, Henar, Calvo, Joaquín, Miquel, Eduardo, Sanz-de-Villalobos, Alejandro, González-Praetorius, Miguel, Torralba, Juan-Ramón, Larrubia
Publikováno v:
Alimentary pharmacologytherapeutics. 55(12)
Hepatitis B virus (HBV)-specific CD8To predict this response with variables involved in T-cell exhaustion for use as a treatment stopping tool.In NUC-treated CHBe(-) patients, we considered a functional response in cases with HBV-specific CD8We devel
Autor:
Julia, Peña-Asensio, Henar, Calvo, Joaquín, Miquel, Eduardo, Sanz-de-Villalobos, Alejandro, González-Praetorius, Miguel, Torralba, Juan-Ramón, Larrubia
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 56(8)
Autor:
Miguel Torralba, Gema Rodríguez, Francisco Javier González Gasca, Fernando Cuadra, José Barberá, Paloma Geijo, Andrea Silva, María Isabel García, Marcos Alexander Ostaiza, Ana María García Pérez, Esther Arroyo, Juan Ramón Larrubia, Almudena Gutiérrez, María Lourdes Porras, Henar Calvo Sánchez, Julia Peña-Asensio, Julio Gabriel Arias, Inés Mendoza
Publikováno v:
Annals of Pharmacotherapy. :106002802311688
Background: The evaluation of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in clinical trials has shown high rates of virological suppression but information about its use in real-life settings is scarce. Objective: To evaluate
Publikováno v:
World Journal of Hepatology
Hepatitis C virus (HCV) infection is an excellent immunological model for understanding the mechanisms developed by non-cytopathic viruses and tumors to evade the adaptative immune response. The antigen-specific cytotoxic T cell response is essential
Publikováno v:
Revista Española de Enfermedades Digestivas. 114
This editorial discusses current challenges in treatment stop in e-antigen-negative chronic hepatitis B, with attention to immunologic and virologic markers associated with functional cure, new therapeutic options for those cases unsuitable for treat